NanoString Technologies

NanoString Technologies

Provides spatial biology and profiling tools

Overview

Company Does Not Provide H1B Sponsorship

NanoString Technologies develops tools for spatial biology that allow researchers to map gene and protein activity directly within tissue samples. These products work by using digital barcodes and imaging to identify where specific biological markers are located without destroying the tissue's physical structure. Unlike competitors that may only look at cells in isolation, NanoString provides a complete view of how cells interact within their natural environment. The company's goal is to speed up scientific discovery in fields like cancer research and drug development by providing high-resolution insights into complex diseases.

About NanoString Technologies

Simplify's Rating
Why NanoString Technologies is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Biotechnology

Healthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Seattle, Washington

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Bruker acquisition integrates NanoString with CellScape for multiomics solutions.
  • 7,000 peer-reviewed publications validate platforms' research impact.
  • High-margin consumables from nCounter and CosMx drive recurring revenue.

What critics are saying

  • Delaware Court injunction halts GeoMx US sales indefinitely.
  • CEO Brad Gray and CFO Tom Bailey departures disrupt leadership.
  • 10x Genomics competition erodes market share in spatial biology.

What makes NanoString Technologies unique

  • NanoString pioneers digital barcoding for spatial transcriptomics via GeoMx and CosMx.
  • nCounter enables direct gene expression profiling without amplification.
  • AtoMx platform integrates multiomics data from tissue architecture.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.2B

Above

Industry Average

Funded Over

18 Rounds

Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison
Coming Soon

Benefits

Health Insurance

Paid Vacation

Paid Holidays

Performance Bonus

Company Equity

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

0%
Securities.io
Jan 30th, 2025
10 Technology Stocks Poised For Future Growth (January 2025)

Growth Comes From InnovationEconomic growth can really come from only two sources: a larger pool of workers and/or resources or a more efficient use of available resources.With limited natural resources and declining demography, the first source of growth is increasingly unlikely to play a big role in Western economies, or in China for that matter. So growth has to come from better use of resources. And a key way to do so is through improved technology.A truck is more efficient than a horse, an excavator is more efficient than a man with a shovel, and a nuclear power plant is more efficient than burning wood or coal. More recently, technology has also started to improve intellectual professions with the rise of computers, the Internet, smartphones, software, and AI.Investing In TechnologyAny investment strategy prioritizing “tech” has probably outperformed the broader markets since the 1990s.The few wise enough investors that held on for decades to stocks of Apple, Amazon, or Tesla have likely seen returns in the 10x, 100x, or even 1000x. Today is no different.However, the most likely to grow exponentially are stocks that are just at the beginning of their journey, more than the established tech giants.So, in this article, we will explore tech companies still at an earlier stage, with large growth potential, a very long runway, and large growing markets in which to expand. We will also cover more than purely software stocks, as technological innovation also concerns hardware.10 Technology Stocks Poised for Future Growth(This list is by nature subjective and does not constitute investment advice).1

GenomeWeb
Dec 23rd, 2024
Delaware Court Grants 10x Genomics Permanent Injunction in Suit Against NanoString

NEW YORK - The US District Court for the District of Delaware today granted 10x Genomics a permanent injunction in its patent infringement suit against NanoString Technologies (now a part of Bruker's spatial biology group).

Genetic Engineering and Biotechnology News
Oct 11th, 2024
Bruker Acquires NanoString for $392.6M

Bruker has acquired NanoString Technologies for approximately $393 million in cash and assumed liabilities, following NanoString's bankruptcy. Bruker has formed a new division, the Bruker Spatial Biology Group, which includes NanoString, Canopy Biosciences, and Acuity Spatial Genomics. The division will maintain its original locations to avoid disruptions. Mark Munch and Todd Garland discuss Bruker's spatial biology strategy and future plans for the acquired technologies.

Business Wire
May 7th, 2024
German Federal Patent Court Invalidates Patent Asserted By 10X Genomics, Delivering Legal Win To Nanostring And Bruker

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the “928 Patent”) in Germany (case 3 Ni 20/22). NanoString is now a Bruker business following Bruker’s asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024. The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString’s CosMx Spatial Molecular Imager (SMI) products for RNA detection. The Federal Patent Court ruled that the German part of the 928 Patent is invalid. “NanoString has consistently maintained that the patents being asserted by 10x Genomics against NanoString’s CosMx SMI products are invalid

GeekWire
May 7th, 2024
Tech Moves: NanoString CEO and CFO depart; Temporal founders swap roles; Gradial adds exec

Brad Gray is stepping down from NanoString after 14 years leading the Seattle biotech company as CEO.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for NanoString Technologies right now.

Find jobs on Simplify and start your career today

We update NanoString Technologies's jobs every few hours, so check again soon! Browse all jobs →